Nucleophosmin 1 Mutation
Showing 26 - 50 of >10,000
The Prevelence of IVS 1-6 [HBB:c.92 +6 T-C] Gene Mutation in
Not yet recruiting
- Beta-Thalassemia
- ARMS
- (no location specified)
May 10, 2022
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)
Active, not recruiting
- BRCA1 Gene Mutation
- +5 more
- Durvalumab
- +3 more
-
Buffalo, New York
- +1 more
Jan 20, 2023
HIV-1-infection Trial in Saint Louis (Biktarvy Tab)
Terminated
- HIV-1-infection
- Biktarvy Tab
-
Saint Louis, MissouriSouthampton Healthcare, Inc.
Jan 3, 2023
Amyotrophic Lateral Sclerosis Trial (ARO-SOD1 Injection, Placebo: ARO-aCSF1 Injection)
Not yet recruiting
- Amyotrophic Lateral Sclerosis
- ARO-SOD1 Injection
- Placebo: ARO-aCSF1 Injection
- (no location specified)
Jul 8, 2023
Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)
Recruiting
- Recurrent IDH1/2 Mutated Glioma
-
Paris, FrancePitie Salpetriere Hospital
Aug 29, 2022
Non Small Cell Lung Cancer Trial (HLX208+HLX10)
Not yet recruiting
- Non Small Cell Lung Cancer
- HLX208+HLX10
- (no location specified)
Nov 30, 2022
Leber Hereditary Optic Neuropathy (LHON) Trial (NFS-02 Injection)
Not yet recruiting
- Leber Hereditary Optic Neuropathy (LHON)
- NFS-02 Injection
- (no location specified)
Apr 6, 2023
Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2
Recruiting
- Hereditary Breast and Ovarian Cancer
-
Barcelona, SpainHospital de la Santa Creu i Sant Pau
Jun 3, 2022
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Sacramento (Niraparib, Niraparib Tosylate Monohydrate,
Recruiting
- ATM Gene Mutation
- +16 more
- Niraparib
- +2 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 27, 2022
Gastric Cancer, Gastric Tumors, Gastric Adenocarcinoma Trial run by the National Cancer Institute (NCI) (Cellvizio (Registered
Not yet recruiting
- Gastric Cancer
- +2 more
- Cellvizio (Registered trademark)Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes
- Olympus GIF 190 endoscope
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Solid Tumor, Adult, NSCLC, Advanced Cancer Trial (Adagrasib, nab-Sirolimus)
Not yet recruiting
- Solid Tumor, Adult
- +4 more
- (no location specified)
Apr 24, 2023
HER2 Insertion Mutation Positive Advanced NSCLC Trial in Changsha (PD-1 Combined With Pyrotinib)
Recruiting
- HER2 Insertion Mutation Positive Advanced NSCLC
- PD-1 Combined With Pyrotinib
-
Changsha, Hunan, ChinaHunan Provincal Tumor Hospital
Mar 1, 2022
Alzheimer's Disease Trial in Colombia (Crenezumab, Placebo)
Active, not recruiting
- Alzheimer's Disease
- Crenezumab
- Placebo
-
Armenia, Colombia
- +3 more
Nov 21, 2022
Non Small Cell Lung Cancer, Solid Tumor Trial in Fairfax (BBP-398 with nivolumab)
Recruiting
- Non Small Cell Lung Cancer
- Solid Tumor
- BBP-398 with nivolumab
-
Springdale, Arkansas
- +6 more
Jan 27, 2023
Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation Trial in Boston (ABT-888, temozolomide)
Active, not recruiting
- Breast Cancer
- +3 more
-
Boston, Massachusetts
- +2 more
Dec 21, 2022
Cancer, Cancer Metastatic, BRAF V600E Trial in Indianapolis (Abemaciclib, LY3214996)
Recruiting
- Cancer
- +6 more
-
Indianapolis, IndianaIndiana University Hospital / IU Simon Cancer Center
Jan 12, 2023
MEN1 Gene Mutation Trial in Basel (Leflunomide 20 mg)
Not yet recruiting
- MEN1 Gene Mutation
- Leflunomide 20 mg
-
Basel, SwitzerlandUnispital Basel
Nov 1, 2022
Metastatic Breast Cancer Trial (Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib)
Not yet recruiting
- Metastatic Breast Cancer
- Lasofoxifene in combination with abemaciclib
- Fulvestrant in combination with abemaciclib
- (no location specified)
Jan 25, 2023
Hyperekplexia in Patients With CTNNB1 Mutation
Not yet recruiting
- Hyperekplexia
- CTNNB1 Gene Mutation
- Questionnaire
- (no location specified)
Feb 11, 2022
PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene
Recruiting
- Non Small Cell Lung Cancer
-
Changsha, Hunan, ChinaYongchang Zhang
Mar 9, 2022
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)
Not yet recruiting
- Metastatic Solid Tumor
- +4 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 12, 2023
Factors Influencing Cascade Testing Among Hereditary
Recruiting
- Breast Carcinoma
- +8 more
- Interview
- +2 more
-
Birmingham, Alabama
- +1 more
Jun 22, 2022